1054 related articles for article (PubMed ID: 35272145)
1. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
2. Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.
Capuano R; Altieri M; Conte M; Bisecco A; d'Ambrosio A; Donnarumma G; Grimaldi E; Coppola N; Medici N; Galdiero M; Tedeschi G; Gallo A
J Neurol; 2022 Dec; 269(12):6185-6192. PubMed ID: 35879563
[TBL] [Abstract][Full Text] [Related]
3. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
Front Immunol; 2022; 13():868915. PubMed ID: 35432335
[TBL] [Abstract][Full Text] [Related]
4. Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab.
Altieri M; Capuano R; Conte M; Donnarumma G; Grimaldi E; Coppola N; Galdiero M; d'Ambrosio A; Tedeschi G; Gallo A
Neurol Sci; 2022 May; 43(5):2947-2949. PubMed ID: 35171373
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab.
Gallo A; Capuano R; Donnarumma G; Bisecco A; Grimaldi E; Conte M; d'Ambrosio A; Coppola N; Galdiero M; Tedeschi G
Neurol Sci; 2021 Sep; 42(9):3523-3526. PubMed ID: 34128150
[TBL] [Abstract][Full Text] [Related]
6. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Capuano R; Prosperini L; Altieri M; Lorefice L; Fantozzi R; Cavalla P; Guaschino C; Radaelli M; Cordioli C; Nociti V; Boffa L; Ragonese P; Di Gregorio M; Pinardi F; Torri Clerici V; De Luca G; Gajofatto A; Paolicelli D; Tortorella C; Gasperini C; Solaro C; Cocco E; Bisecco A; Gallo A
Mult Scler; 2023 Jun; 29(7):856-865. PubMed ID: 37165941
[TBL] [Abstract][Full Text] [Related]
7. mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity-Does it matter?
Tütüncü M; Demir S; Arslan G; Dinç Ö; Şen S; Gündüz T; Uzunköprü C; Gümüş H; Tütüncü M; Akçin R; Özakbaş S; Köseoğlu M; Bünül SD; Gezen O; Tezer DÇ; Baba C; Özen PA; Koç R; Elverdi T; Uygunoğlu U; Kürtüncü M; Beckmann Y; Doğan İG; Turan ÖF; Boz C; Terzi M; Tuncer A; Saip S; Karabudak R; Kocazeybek B; Efendi H; Bilge U; Siva A
Mult Scler Relat Disord; 2023 Jul; 75():104761. PubMed ID: 37247488
[TBL] [Abstract][Full Text] [Related]
8. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.
Sormani MP; Inglese M; Schiavetti I; Carmisciano L; Laroni A; Lapucci C; Da Rin G; Serrati C; Gandoglia I; Tassinari T; Perego G; Brichetto G; Gazzola P; Mannironi A; Stromillo ML; Cordioli C; Landi D; Clerico M; Signoriello E; Frau J; Ferrò MT; Di Sapio A; Pasquali L; Ulivelli M; Marinelli F; Callari G; Iodice R; Liberatore G; Caleri F; Repice AM; Cordera S; Battaglia MA; Salvetti M; Franciotta D; Uccelli A;
EBioMedicine; 2021 Oct; 72():103581. PubMed ID: 34563483
[TBL] [Abstract][Full Text] [Related]
9. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies.
Maniscalco GT; Liotti A; Ferrara AL; Prestipino E; Salvatore S; Di Battista ME; Moreggia O; Di Giulio Cesare D; Vastano R; Belardo M; Napolitano M; Ranieri A; Longo K; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Dec; 68():104371. PubMed ID: 36544318
[TBL] [Abstract][Full Text] [Related]
10. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
[TBL] [Abstract][Full Text] [Related]
12. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
14. Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose.
Ruggieri S; Aiello A; Tortorella C; Navarra A; Vanini V; Meschi S; Lapa D; Haggiag S; Prosperini L; Cuzzi G; Salmi A; Quartuccio ME; Altera AMG; Garbuglia AR; Ascoli Bartoli T; Galgani S; Notari S; Agrati C; Puro V; Nicastri E; Gasperini C; Goletti D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239872
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
[TBL] [Abstract][Full Text] [Related]
16. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
[TBL] [Abstract][Full Text] [Related]
17. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
[TBL] [Abstract][Full Text] [Related]
18. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
19. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
20. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations.
König M; Lorentzen ÅR; Torgauten HM; Tran TT; Schikora-Rustad S; Vaage EB; Mygland Å; Wergeland S; Aarseth J; Aaberge IAS; Torkildsen Ø; Holmøy T; Berge T; Myhr KM; Harbo HF; Andersen JT; Munthe LA; Søraas A; Celius EG; Vaage JT; Lund-Johansen F; Nygaard GO
J Neurol Neurosurg Psychiatry; 2023 Jan; 94(1):19-22. PubMed ID: 34670844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
